ClinicalTrials.gg
CompletedNCT01178827Updated Feb 26, 2016Results posted

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

A Phase 4 interventional study of trospium chloride and oxybutynin IR in Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2016-02-26.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.

Enrollment
21st of 22
20 · median 265
Started
2010
with 3 others
Phase 4
9 of 28
none open now
Registered
17th of 28
by date

Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2010, is one of 9 in phase 4, and was the 17th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →

Who these studies take

Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Urinary Bladder, Overactive by AbbVie as a file.
02

Study summary

This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presents symptoms of overactive bladder
  • Patient has age associated memory impairment
  • No acute or unstable medical conditions

Exclusion criteria

Exclusion Criteria:

  • History of alcohol or substance abuse within 1 year prior to study
  • Has donated in excess of 500mL of blood or plasma in the 30 days prior to study
  • Has known bleeding disorder (hemophilia)
  • Previous abdominal bypass surgery for obesity
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sanctura XR®

    Sanctura XR® (trospium chloride), 60mg once daily for 10 days

    Drug: trospium chloride

  • Active comparator
    Oxybutynin IR

    Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days

    Drug: oxybutynin IR

  • Placebo comparator
    Oxybutynin IR placebo

    Oxybutynin IR placebo three times daily for 2 days

    Drug: oxybutynin IR placebo

Interventions

  • trospium chloride (60mg) once daily for 10 days

    Also known as: Sanctura XR®

  • oxybutynin IR (5 mg) three times daily for 2 days

  • Drugoxybutynin IR placebo

    oxybutynin IR placebo three times daily for 2 days

06

What researchers measure

Primary outcomes

  1. Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose

    Cerebral spinal fluid levels of Sanctura XR® at Day 10 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Sanctura XR®.

    Time frame: Day 10 Post-Dose

  2. Cerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose

    Cerebral spinal fluid levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Oxybutynin IR.

    Time frame: Day 2 Post-Dose

Secondary outcomes

  1. Plasma Levels of Sanctura XR® at Day 10 Post-dose

    Plasma levels of Sanctura XR® at Day 10 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.

    Time frame: Day 10 Post-Dose

  2. Plasma Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose

    Plasma levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.

    Time frame: Day 2 Post-Dose

  3. Change From Baseline in Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) up to Day 10

    Change from Baseline in Total Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory and a negative change from baseline indicates worsened memory.

    Time frame: Baseline, 10 Days

  4. Change From Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10

    Change from Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.

    Time frame: Baseline, 10 Days

  5. Change From Baseline in Total Recall Score as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) up to Day 10

    Change from Baseline in total recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory.

    Time frame: Baseline, 10 Days

  6. Change From Baseline in Delayed Recall Score as Measured by the BVMT-R up to Day 10

    Change from Baseline in delayed recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.

    Time frame: Baseline, 10 Days

07

Results

Posted Aug 16, 2012

Participant flow

Participant flow — Overall Study
MilestoneSanctura XR®Oxybutynin IROxybutynin IR Placebo
Started6104
Completed6104
Not completed000

Outcome measures

PrimaryCerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose

Cerebral spinal fluid levels of Sanctura XR® at Day 10 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Sanctura XR®.

Time frame:
Day 10 Post-Dose
Reported as:
Mean · Nanograms (ng) per milliliter (mL)
Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose
Nanograms (ng) per milliliter (mL)Sanctura XR®Oxybutynin IROxybutynin IR Placebo
Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-doseNA ± NA——
PrimaryCerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose

Cerebral spinal fluid levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Oxybutynin IR.

Time frame:
Day 2 Post-Dose
Reported as:
Mean · Nanograms (ng) per milliliter (mL)
Cerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose
Nanograms (ng) per milliliter (mL)Sanctura XR®Oxybutynin IROxybutynin IR Placebo
Oxybutynin—0.0597 ± 0.0309—
N-Desethyl-Oxybutynin—0.386 ± 0.235—
SecondaryPlasma Levels of Sanctura XR® at Day 10 Post-dose

Plasma levels of Sanctura XR® at Day 10 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.

Time frame:
Day 10 Post-Dose
Reported as:
Mean · Nanograms (ng) per milliliter (mL)
Plasma Levels of Sanctura XR® at Day 10 Post-dose
Nanograms (ng) per milliliter (mL)Sanctura XR®Oxybutynin IROxybutynin IR Placebo
Plasma Levels of Sanctura XR® at Day 10 Post-dose1.47 ± 1.03——
SecondaryPlasma Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose

Plasma levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.

Time frame:
Day 2 Post-Dose
Reported as:
Mean · Nanograms (ng) per milliliter (mL)
Plasma Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose
Nanograms (ng) per milliliter (mL)Sanctura XR®Oxybutynin IROxybutynin IR Placebo
Oxybutynin—8.80 ± 2.84—
N-Desethyl-Oxybutynin—47.0 ± 11.2—
SecondaryChange From Baseline in Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) up to Day 10

Change from Baseline in Total Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory and a negative change from baseline indicates worsened memory.

Time frame:
Baseline, 10 Days
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) up to Day 10
Scores on a ScaleSanctura XR®Oxybutynin IROxybutynin IR Placebo
Baseline22.5 ± 2.924.4 ± 3.324.0 ± 3.7
Change from Baseline up to Day 10-0.3 ± 3.3-3.3 ± 5.4-2.0 ± 4.8
SecondaryChange From Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10

Change from Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.

Time frame:
Baseline, 10 Days
Reported as:
Mean · Scores on a Scale
Change From Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10
Scores on a ScaleSanctura XR®Oxybutynin IROxybutynin IR Placebo
Baseline8.2 ± 1.29.4 ± 2.18.8 ± 2.1
Change from Baseline up to Day 10-1.2 ± 1.5-1.3 ± 1.6-0.3 ± 3.7
SecondaryChange From Baseline in Total Recall Score as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) up to Day 10

Change from Baseline in total recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory.

Time frame:
Baseline, 10 Days
Reported as:
Mean · Scores on a Scale
Change From Baseline in Total Recall Score as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) up to Day 10
Scores on a ScaleSanctura XR®Oxybutynin IROxybutynin IR Placebo
Baseline15.8 ± 6.620.3 ± 9.916.8 ± 11.3
Change from Baseline up to Day 101.2 ± 7.4-1.1 ± 5.30.0 ± 3.5
SecondaryChange From Baseline in Delayed Recall Score as Measured by the BVMT-R up to Day 10

Change from Baseline in delayed recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.

Time frame:
Baseline, 10 Days
Reported as:
Mean · Scores on a Scale
Change From Baseline in Delayed Recall Score as Measured by the BVMT-R up to Day 10
Scores on a ScaleSanctura XR®Oxybutynin IROxybutynin IR Placebo
Baseline6.0 ± 4.28.0 ± 3.64.5 ± 5.3
Change from Baseline up to Day 100.2 ± 3.4-1.8 ± 3.52.3 ± 3.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sanctura XR®—0/6 (0%)5/6 (83.3%)
Oxybutynin IR—0/10 (0%)7/10 (70%)
Oxybutynin IR Placebo—0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventSanctura XR®Oxybutynin IROxybutynin IR Placebo
HeadacheNervous system disorders5/65/102/4
Back PainMusculoskeletal and connective tissue disorders4/63/101/4
Pain in ExtremityMusculoskeletal and connective tissue disorders1/64/102/4
NauseaGastrointestinal disorders2/62/100/4
Muscle SpasmsMusculoskeletal and connective tissue disorders1/61/101/4
Dry MouthGastrointestinal disorders0/62/100/4
DizzinessNervous system disorders1/62/100/4
LethargyNervous system disorders1/60/100/4
TinnitusEar and labyrinth disorders1/60/100/4
DiarrhoeaGastrointestinal disorders1/60/100/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sanctura XR®Oxybutynin IROxybutynin IR PlaceboTotal
Mean74.4 ± 6.368.3 ± 6.177.6 ± 12.372.0 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Sanctura XR®Oxybutynin IROxybutynin IR PlaceboTotal
Female36211
Male3429
08

Study locations

1 site
  • Salt Lake City, Utah, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2010
First posted
Aug 10, 2010
Start
Aug 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Aug 16, 2012
Last update
Feb 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01178827
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Aug 10, 2010
Start date
Aug 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Aug 16, 2012
Last update
Feb 26, 2016

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trospium chloride

Start the discussion